Keith Mallinson

Keith Mallinson has more than 25 years of experience in the telecommunications industry: as a research analyst, consultant and testifying expert witness. Complementing his industry focus, he has a broad skill set including technologies, market analysis, regulation, economics and finance. He has published numerous articles and speaks publicly at major industry events on a wide variety of topics including market developments and competition in next generation mobile network technologies, semiconductors, patents and licensing.

Prior to founding expert consulting firm WiseHarbor in 2006, Mallinson led industry analyst firm Yankee Group’s global Wireless/Mobile research and consulting team as an Executive Vice President, based in Boston from 2000. Until then, he had overall responsibility for the firm’s European division, as Managing Director from 1995. Prior to that he was the European Research Director.

He started his career in military communications design, project management and commercial systems engineering at the UK Ministry of Defence. He also worked as an engineer at an electronic security systems company. For several years he was a director at a seed capital investment firm specializing in ICT and biotechnology.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More